Lucentis Treatment Safe for Wet Macular Degeneration

Lucentis, a drug that has been approved for treating wet macular degeneration has been shown to be a safe and effective treatment for the eye disease.  The safety of Lucentis as a treatment for macular degeneration comes after an analysis of 4 large clinical trials.

The findings were presented at the 2008 joint meeting of the American Academy of Ophthalmology and the European Society of Opthalmology.

The trials used evaluating the safety of Lucentis as a treatment of macular degeneration included the MARINA, ANCHOR, PIER and SAILOR trials, and included 3701 patients that had received a total of 28,547 injections of Lucentis.

Incidence of intraocular inflammation was somewhat higher in the MARINA and ANCHOR trials for Lucentis treated patients when compared to the sham treatment or the photodynamic thearapy for macular degeneration.  The rates of serious endophthalmitis per injection was very low for those treated with Lucentis when compared to those in the control group.

In the Lucentis vs the control group, the incidence of cataracts was comparable in the MARINA trial, but higher with Lucentis in the other trials.

The rate of stroke in the Lucentis group treated for macular degeneration was shown to be non significant.

The study showed that there were no safety concerns that should prevent physicians from using Lucentis to treat patients suffering from macular degeneration.